Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Maltotetraose
- DrugBank Accession Number
- DB02237
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Maltotetraose (DB02237)
- Weight
- Average: 666.579
Monoisotopic: 666.221858372 - Chemical Formula
- C24H42O21
- Synonyms
- alpha-1,4-tetraglucose
- Amylotetraose
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UGlucan 1,4-alpha-maltotetraohydrolase Not Available Pseudomonas stutzeri UNeopullulanase 2 Not Available Thermoactinomyces vulgaris - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The risk or severity of bleeding can be increased when Maltotetraose is combined with Acenocoumarol. Ambroxol The risk or severity of methemoglobinemia can be increased when Maltotetraose is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Maltotetraose is combined with Articaine. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Maltotetraose. Benzocaine The risk or severity of methemoglobinemia can be increased when Maltotetraose is combined with Benzocaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oligosaccharides. These are carbohydrates made up of 3 to 10 monosaccharide units linked to each other through glycosidic bonds.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Oligosaccharides
- Alternative Parents
- Alkyl glycosides / O-glycosyl compounds / Fatty alcohols / Oxanes / Beta-hydroxy aldehydes / Alpha-hydroxyaldehydes / Secondary alcohols / Polyols / Oxacyclic compounds / Acetals show 3 more
- Substituents
- Acetal / Alcohol / Aldehyde / Aliphatic heteromonocyclic compound / Alkyl glycoside / Alpha-hydroxyaldehyde / Beta-hydroxy aldehyde / Carbonyl group / Fatty acyl / Fatty acyl glycoside show 12 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- maltotetraose tetrasaccharide (CHEBI:28460)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- BO88JLT87R
- CAS number
- 34612-38-9
- InChI Key
- UYQJCPNSAVWAFU-KVXMBEGHSA-N
- InChI
- InChI=1S/C24H42O21/c25-1-6(30)11(32)19(7(31)2-26)43-23-17(38)14(35)21(9(4-28)41-23)45-24-18(39)15(36)20(10(5-29)42-24)44-22-16(37)13(34)12(33)8(3-27)40-22/h1,6-24,26-39H,2-5H2/t6-,7+,8+,9+,10+,11+,12+,13-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+/m0/s1
- IUPAC Name
- (2R,3R,4R,5R)-4-{[(2R,3R,4R,5S,6R)-5-{[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,3,5,6-tetrahydroxyhexanal
- SMILES
- OC[C@@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C=O
References
- Synthesis Reference
Yoshiyuki Takasaki, "Method of using G-4 amylase to produce high maltotetraose and high maltose content starch hydrolysates." U.S. Patent US4925795, issued November, 1985.
US4925795- General References
- Not Available
- External Links
- KEGG Compound
- C02052
- PubChem Compound
- 123966
- PubChem Substance
- 46506588
- ChemSpider
- 110488
- ChEBI
- 28460
- ZINC
- ZINC000087493170
- Wikipedia
- Maltodextrin
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 221.0 mg/mL ALOGPS logP -2.6 ALOGPS logP -8.9 Chemaxon logS -0.48 ALOGPS pKa (Strongest Acidic) 11.7 Chemaxon pKa (Strongest Basic) -3.7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 21 Chemaxon Hydrogen Donor Count 14 Chemaxon Polar Surface Area 355.67 Å2 Chemaxon Rotatable Bond Count 14 Chemaxon Refractivity 134.59 m3·mol-1 Chemaxon Polarizability 61.46 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.8748 Blood Brain Barrier + 0.6207 Caco-2 permeable - 0.8836 P-glycoprotein substrate Non-substrate 0.5394 P-glycoprotein inhibitor I Non-inhibitor 0.7589 P-glycoprotein inhibitor II Non-inhibitor 0.9142 Renal organic cation transporter Non-inhibitor 0.8144 CYP450 2C9 substrate Non-substrate 0.8451 CYP450 2D6 substrate Non-substrate 0.8853 CYP450 3A4 substrate Non-substrate 0.658 CYP450 1A2 substrate Non-inhibitor 0.961 CYP450 2C9 inhibitor Non-inhibitor 0.9376 CYP450 2D6 inhibitor Non-inhibitor 0.9399 CYP450 2C19 inhibitor Non-inhibitor 0.9083 CYP450 3A4 inhibitor Non-inhibitor 0.9645 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8898 Ames test Non AMES toxic 0.8628 Carcinogenicity Non-carcinogens 0.9551 Biodegradation Not ready biodegradable 0.6632 Rat acute toxicity 1.0242 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9517 hERG inhibition (predictor II) Non-inhibitor 0.8283
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 225.18828 predictedDeepCCS 1.0 (2019) [M+H]+ 226.91199 predictedDeepCCS 1.0 (2019) [M+Na]+ 233.17906 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Pseudomonas stutzeri
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- alpha-amylase activity
- Gene Name
- amyP
- Uniprot ID
- P13507
- Uniprot Name
- Glucan 1,4-alpha-maltotetraohydrolase
- Molecular Weight
- 59875.725 Da
References
- Kind
- Protein
- Organism
- Thermoactinomyces vulgaris
- Pharmacological action
- Unknown
- General Function
- Hydrolyzes pullulan efficiently but only a small amount of starch. Endohydrolysis of 1,4-alpha-glucosidic linkages in pullulan to form panose. Cleaves also (1-6)-alpha-glucosidic linkages to form maltotriose.
- Specific Function
- metal ion binding
- Gene Name
- tvaII
- Uniprot ID
- Q08751
- Uniprot Name
- Neopullulanase 2
- Molecular Weight
- 67466.71 Da
References
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52